The historical rank and industry rank for Lexaria Bioscience's FCF Margin % or its related term are showing as below:
LEXX'
s FCF Margin % Range Over the Past 10 Years
Min: -2677.43 Med: -1577.66 Max: -562.79
Current: -2573.1
During the past 13 years, the highest FCF Margin % of Lexaria Bioscience was -562.79%. The lowest was -2677.43%. And the median was -1577.66%.
LEXX's FCF Margin % is ranked worse than 85.71% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs LEXX: -2573.10
Lexaria Bioscience FCF Margin % Related Terms
Lexaria Bioscience FCF Margin % Historical Data
* Premium members only.
The historical data trend for Lexaria Bioscience's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lexaria Bioscience's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexaria Bioscience FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexaria Bioscience (LEXX) has a FCF Margin % of -11,100.00% as of Feb. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Lexaria Bioscience and its competitors. According to the industry distribution chart, Lexaria Bioscience ranks #822 out of 959 companies in the Biotechnology industry, placing it in the top 85.7%.
Is Lexaria Bioscience's FCF Margin % too high?
Lexaria Bioscience's current FCF Margin % is -11,100.00%. Based on the distribution chart, Lexaria Bioscience ranks #822 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lexaria Bioscience has a GF Score™ of 28/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's FCF Margin % compare to MBRX and ICU?
According to the Biotechnology industry distribution chart, Lexaria Bioscience ranks #822 out of 959 companies for FCF Margin %. This places Lexaria Bioscience in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Lexaria Bioscience and its competitors. Lexaria Bioscience's current FCF Margin % is -11,100.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.75, compared to a current price of $0.54 — trading 27.7% below its estimated fair value. The current FCF Margin % is -11,100.00%. Lexaria Bioscience's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current FCF Margin % is -11,100.00% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lexaria Bioscience (LEXX) Overvalued in 2026?
Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be undervalued.
The current stock price of $0.54 is trading 27.7% below its estimated GF Value™ of $0.75.
GuruFocus considers Lexaria Bioscience to be Modestly Undervalued.
Key valuation signals for LEXX:
FCF Margin %: -11,100.00%
GF Value™: $0.75 vs. price of $0.54 (27.7% below fair value)
No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
28GF Score
Get the complete analysis for LEXX
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEXX has been successfully added to your 
